기업 프로필 · Healthcare

Bio-Techne Corp

TECH · 미국
거래소
미국
국가 / 지역
USA
상장일
1989년 2월 9일
직원 수
3,100
웹사이트
www.bio-techne.com
현재가
$57.94
실시간 · 2026년 6월 18일
적정 매수가
≤ $35
안전마진 진입가
베일리 성장 점수
27/100
약함
내재가치 · 3단계 구간 현재가 $57.94 실시간 · 낙관적 상단 위 · 미래 성장 과도 반영

종합 밸류에이션 구간 · 보수적 $24–$30 / 적정 $31–$42 / 낙관적 $45–$56. $57.94 기준, 낙관적 상단 위 · 미래 성장 과도 반영.

보고서 발행 시 $51.68(2026년 5월 31일)

이 종목에 대한 리포트가 아직 해당 언어로 없습니다.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

시가총액US$86.11억
매출 (TTM)US$12.11억
EBITDAUS$3.66억
순이익률9.05%
ROE5.34%
PER (TTM)78.57
선행 PER26.95
PEG0.76
EPSUS$0.70
배당수익률0.57%
52주 범위US$43.12 – US$71.93
애널리스트 목표주가US$61.69
애널리스트 평가4.1 / 5

데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.

연혁

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.

업계 내 위치

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.